Federal Register / Vol. 79, No. 83 / Wednesday, April 30, 2014 / Notices 24419 

Bldg., Rm. 3334, 1301 Constitution Ave. 

NW., Washington, DC 20460–0001. The 

Public Reading Room is open from 8:30 

a.m. to 4:30 p.m., Monday through 

Friday, excluding legal holidays. The 

telephone number for the Public 

Reading Room is (202) 566–1744, and 

the telephone number for the OPP 

Docket is (703) 305–5805. Please review 

the visitor instructions and additional 

information, available at http://

www.epa.gov/dockets. 

FOR FURTHER INFORMATION CONTACT: Lois 

Rossi, Registration Division (7505P), 

Office of Pesticide Programs, 

Environmental Protection Agency, 1200 

Pennsylvania Ave. NW., Washington, 

DC 20460–0001; telephone number: 

(703)305–7090; email address: 

RDFRNotices@epa.gov. 

SUPPLEMENTARY INFORMATION: 

I. General Information 

A. Does this action apply to me? 

You may be potentially affected by 

this action if you are an agricultural 

producer, food manufacturer, or 

pesticide manufacturer. The following 

list of North American Industrial 

Classification System (NAICS) codes is 

not intended to be exhaustive, but rather 

provides a guide to help readers 

determine whether this document 

applies to them. Potentially affected 

entities may include: 

• Crop production (NAICS code 111). 

• Animal production (NAICS code 

112). 

• Food manufacturing (NAICS code 

311). 

• Pesticide manufacturing (NAICS 

code 32532). 

B. What should I consider as I prepare 

my comments for EPA? 

1. Submitting CBI. Do not submit this 

information to EPA through 

www.regulations.gov or email. Clearly 

mark the part or all of the information 

that you claim to be CBI. For CBI 

information in a disk or CD–ROM that 

you mail to EPA, mark the outside of the 

disk or CD–ROM as CBI and then 

identify electronically within the disk or 

CD–ROM the specific information that 

is claimed as CBI. In addition to one 

complete version of the comment that 

includes information claimed as CBI, a 

copy of the comment that does not 

contain the information claimed as CBI 

must be submitted for inclusion in the 

public docket. Information so marked 

will not be disclosed except in 

accordance with procedures set forth in 

40 CFR part 2. 

2. Tips for preparing your comments. 

When submitting comments, remember 

to: 

i. Identify the document by docket ID 

number and other identifying 

information (subject heading, Federal 

Register date and page number). 

ii. Follow directions. The Agency may 

ask you to respond to specific questions 

or organize comments by referencing a 

Code of Federal Regulations (CFR) part 

or section number. 

iii. Explain why you agree or disagree; 

suggest alternatives and substitute 

language for your requested changes. 

iv. Describe any assumptions and 

provide any technical information and/ 

or data that you used. 

v. If you estimate potential costs or 

burdens, explain how you arrived at 

your estimate in sufficient detail to 

allow for it to be reproduced. 

vi. Provide specific examples to 

illustrate your concerns and suggest 

alternatives. 

vii. Explain your views as clearly as 

possible, avoiding the use of profanity 

or personal threats. 

viii. Make sure to submit your 

comments by the comment period 

deadline identified. 

3. Environmental justice. EPA seeks to 

achieve environmental justice, the fair 

treatment and meaningful involvement 

of any group, including minority and/or 

low income populations, in the 

development, implementation, and 

enforcement of environmental laws, 

regulations, and policies. To help 

address potential environmental justice 

issues, the Agency seeks information on 

any groups or segments of the 

population who, as a result of their 

location, cultural practices, or other 

factors, may have atypical or 

disproportionately high and adverse 

human health impacts or environmental 

effects from exposure to the pesticide(s) 

discussed in this document, compared 

to the general population. 

II. What action is the Agency taking? 

Under section 18 of the Federal 

Insecticide, Fungicide, and Rodenticide 

Act (FIFRA) (7 U.S.C. 136p), at the 

discretion of the EPA Administrator, a 

Federal or State agency may be 

exempted from any provision of FIFRA 

if the EPA Administrator determines 

that emergency conditions exist which 

require the exemption. The Wyoming 

Department of Agriculture has requested 

the EPA Administrator to issue a 

specific exemption for the use of 

diflubenzuron on alfalfa to control 

grasshoppers and Mormon crickets. 

Information in accordance with 40 CFR 

part 166 was submitted as part of this 

request. 

As part of this request, the applicant 

asserts that projected population levels 

for these damaging insect pests are 

expected to be extremely high for the 

2014 season. The applicant claims that 

registered alternatives will not provide 

adequate control to avert significant 

economic losses from occurring. 

The Applicant proposes to make no 

more than two applications of 

diflubenzuron, at a rate of 0.032 lbs. 

active ingredient (a.i.) (equivalent to 2 

fl. oz. of product containing 2 lbs. a.i. 

per gallon). Application could be made 

on up to 26,000 acres of alfalfa, from the 

date of approval, if granted, until 

October 31, 2014, in the state of 

Wyoming. If the maximum proposed 

acreage were treated at the maximum 

rate, a total of 814 lbs. a.i. (407 gallons 

formulated product) could be applied. 

This notice does not constitute a 

decision by EPA on the application 

itself. The regulations governing FIFRA 

section 18 require publication of a 

notice of receipt of an application for a 

specific exemption proposing use which 

is supported by the Inter-Regional 

Project Number 4 (IR–4) program and 

has been requested in 5 or more 

previous years, and a petition for 

tolerance has not yet been submitted to 

the Agency. 

The notice provides an opportunity 

for public comment on the application. 

The Agency will review and consider 

all comments received during the 

comment period in determining 

whether to issue the specific exemption 

requested by the Wyoming Department 

of Agriculture. 

List of Subjects 

Environmental protection, Pesticides 

and pests. 

Dated: April 18, 2014. 

Lois Rossi, 

Director, Registration Division, Office of 

Pesticide Programs. 

[FR Doc. 2014–09667 Filed 4–29–14; 8:45 am] 

BILLING CODE 6560–50–P 

ENVIRONMENTAL PROTECTION 

AGENCY 

[EPA–HQ–OW–2014–0138; FRL–9910–21– 

OW] 

Peer Review of the Draft Health Effects 

Documents for Perfluorooctanoic Acid 

and Perfluorooctane Sulfonate— 

Interim List of Potential Peer 

Reviewers 

AGENCY: Environmental Protection 

Agency (EPA). 

ACTION: Notice; request for public 

comments. 

SUMMARY: Environmental Protection 

Agency (EPA) requests public comments 

on the interim list of candidates being 

mstockstill on DSK4VPTVN1PROD with NOTICES

24420 Federal Register / Vol. 79, No. 83 / Wednesday, April 30, 2014 / Notices 

1CCL3 is a list of contaminants that are currently 

not subject to any proposed or promulgated 

national primary drinking water regulations, that 

are known or anticipated to occur in public water 

systems, and which may require regulation under 

the Safe Drinking Water Act (SDWA). Additional 

information about the CCL3 can be found at the 

following Web site: http://water.epa.gov/scitech/ 

drinkingwater/dws/ccl/ccl3.cfm. 

2EPA uses the Unregulated Contaminant 

Monitoring (UCM) program to collect data for 

unregulated contaminants suspected to be present 

in drinking water. Results from UCMR3 can be 

examined as they become available at the following 

Web site: http://water.epa.gov/lawsregs/rulesregs/

sdwa/ucmr/ucmr3/. 

considered as peer reviewers for the 

contractor-managed external peer 

review of the draft documents entitled, 

‘‘Health Effects Document for 

Perfluorooctanoic Acid’’ and ‘‘Health 

Effects Document for Perfluorooctane 

Sulfonate.’’ This notice provides the 

names, professional affiliations, 

expertise, education, and professional 

experience of the candidate reviewers. 

The public is requested to provide 

relevant information or documentation 

on the candidates who are being 

evaluated by the contractor (Versar, 

Inc.). Once the public comments on the 

interim list of candidates have been 

reviewed and considered, Versar will 

select the final six to seven peer 

reviewers who, collectively, best 

provide expertise spanning the multiple 

subject matter areas covered by the draft 

documents and, to the extent feasible, 

best provide a balance of perspectives. 

DATES: The public comment period on 

the interim list of peer reviewers begins 

on April 30, 2014 and ends on May 21, 

2014. 

ADDRESSES: Any interested person or 

organization may submit comments on 

the interim list of peer reviewers. Public 

comments should be submitted to the 

EPA contractor, Versar, Inc., no later 

than May 21, 2014, by one of the 

following methods: 

• Online: http://

peerreview.versar.com/epa/pfoa/

interim-list.html. 

• Email: peerreview@versar.com 

(subject line: PFOA/PFOS Peer Review). 

• Mail: Versar, Inc., 6850 Versar 

Center, Springfield, VA 22151 (ATTN: 

Betzy Colon). 

Please be advised that public 

comments are subject to release under 

the Freedom of Information Act. 

FOR FURTHER INFORMATION CONTACT: 

Questions concerning the comment 

process or Web site should be directed 

to the EPA contractor, Versar, Inc., at 

6850 Versar Center, Springfield, VA 

22151; by email peerreview@versar.com 

(subject line: PFOA/PFOS Peer Review); 

or by phone: (703) 642–6727 (ask for 

Betzy Colon). For additional 

information concerning the health 

effects documents, please contact Joyce 

Donohue at U.S. EPA, Office of Water, 

Health and Ecological Criteria Division 

(Mail Code 4304T), 1200 Pennsylvania 

Avenue NW., Washington, DC 20460; 

telephone: (202) 566–1098; or email: 

donohue.joyce@epa.gov. 

SUPPLEMENTARY INFORMATION: 

I. Background Information on the Draft 

Health Effects Documents 

EPA has prepared draft health effects 

documents for Perfluorooctanoic Acid 

(PFOA) and Perfluorooctane Sulfonate 

(PFOS) for purposes of public comment 

(scientific views) and peer review. EPA 

will consider any public comments and 

peer reviewer comments submitted in 

accordance with the Federal Register 

notice dated February 24, 2014 (http:// 

www.gpo.gov/fdsys/pkg/FR-2014-02-28/

pdf/2014-04455.pdf) when finalizing the 

documents. Once the health effects 

documents are finalized, they will be 

utilized to develop lifetime health 

advisory values for each chemical. 

PFOA and PFOS are listed on the third 

contaminant Candidate List (CCL3) 1

and both chemicals are currently being 

monitored under the third Unregulated 

Contaminant Monitoring Rule 

(UCMR3) 2. The draft documents are 

available through www.regulations.gov 

(docket ID number EPA–HQ–OW–2014– 

0138) and at http://peer

review.versar.com/epa/pfoa. 

II. Process of Obtaining Candidate 

Reviewers 

On February 24, 2014, EPA released 

the draft health effects documents on 

PFOA and PFOS for the purposes of 

public comment and peer review. 

Consistent with guidelines for the peer 

review of highly influential scientific 

assessments, EPA tasked a contractor 

(Versar, Inc.) to assemble six to seven 

scientific experts to evaluate the draft 

documents. As part of the peer review 

process, a public nomination period was 

held from February 24, 2014 to March 

21, 2014, during which members of the 

public were able to nominate scientific 

experts with knowledge and experience 

in one or more of the following areas: 

(1) Epidemiology, (2) toxicology (liver 

effects, immunotoxicity, neurotoxicity, 

developmental and reproductive 

toxicology, etc.), (3) membrane 

transport, (4) human health risk 

assessment, (5) pharmacokinetic 

models, and (6) mode-of-action for 

cancer and noncancer effects. Versar 

also conducted an independent search 

for scientific experts to augment the list 

of publically-nominated candidates. In 

total, Versar evaluated the 29 candidates 

nominated during the public 

nomination period and identified by 

Versar. 

Selection Process: Versar considered 

and screened all candidates against the 

selection criteria described in the 

Federal Register dated February 24, 

2014 (http://www.gpo.gov/fdsys/pkg/FR2014-02-28/pdf/2014-04455.pdf), which 

included having demonstrated expertise 

in the areas described above, being free 

of any conflict of interest, and being 

available to participate in-person in a 

two-day peer review meeting in the 

Washington, DC area (exact date to be 

determined). Following the screening 

process, Versar narrowed the list of 

potential reviewers to 15 candidates. 

This Federal Register notice is to solicit 

comments on the interim list of 15 

candidates. The public is requested to 

provide relevant information or 

documentation on the candidates who 

are being evaluated by Versar. Once the 

public comments on the interim list of 

candidates have been reviewed and 

considered, Versar will select the final 

six to seven peer reviewers. Additional 

information on the scientific peer 

review process can be found at: http:// 

peerreview.versar.com/epa/pfoa. 

Responsibilities of Peer Reviewers: 

Peer reviewers will be charged with 

evaluating and preparing written 

comments on the draft PFOA and PFOS 

health effects documents. Specifically, 

reviewers will provide general 

comments, their overall impressions of 

the documents, and respond to 12 

charge questions. This includes 

determining the appropriateness of the 

quality, accuracy, and relevance of the 

data in the documents. Any public 

comments submitted to EPA’s public 

docket (docket ID number EPA–HQ– 

OW–2014–0138) during each 

document’s 60-day public comment 

period will also be provided to the peer 

reviewers for their consideration. In 

addition, peer reviewers will participate 

in a two-day peer review meeting to 

discuss the scientific basis supporting 

EPA’s draft health effects documents. 

The meeting will be held in the 

Washington, DC metro area and is 

anticipated to take place in the late July 

or August timeframe. Following the peer 

review meeting, Versar will provide a 

peer review summary report to EPA 

containing the comments and 

recommendations from the peer 

reviewers. The final peer review report 

will also be made available to the 

public. In preparing the final health 

effects documents, EPA will consider 

Versar, Inc.’s report of the comments 

and recommendations from the external 

peer review meeting, as well as written 

public comments received through the 

official public docket. 

mstockstill on DSK4VPTVN1PROD with NOTICES

Federal Register / Vol. 79, No. 83 / Wednesday, April 30, 2014 / Notices 24421 

III. Interim List of Peer Reviewers 

Following are the names, professional 

affiliations, expertise, education, and 

professional experience of the current 

candidates being considered for the 

external peer review of the draft PFOA 

and PFOS Health Effects documents. 

After review and consideration of any 

public comments received, Versar will 

select from this list the final six to seven 

peer reviewers who, collectively, best 

provide expertise spanning the multiple 

areas listed above and, to the extent 

feasible, best provide a balance of 

perspectives. Once the final six to seven 

peer reviewers are selected by Versar, a 

third Federal Register notice will be 

published at least 30 days prior to the 

external peer review meeting with the 

names of the final peer reviewers, along 

with information on the meeting date, 

location, and registration details. 

1. John C. Bailar III, M.D., Ph.D., 

University of Chicago (Emeritus). 

i. Expertise: Epidemiology and 

Human Health Risk Assessment. 

ii. Education: Yale University, M.D. 

(1955) and American University, Ph.D. 

in Statistics (1973). 

iii. Professional Experience: Dr. Bailar 

is Professor Emeritus at the University 

of Chicago, where he was founding 

Chair of the Department of Health 

Studies. Prior to joining the University 

of Chicago, Dr. Bailar was at the U.S. 

National Cancer Institute from 1956– 

1980, Harvard University 1980–1988, 

and McGill University (where he was 

Chair of Epidemiology and Biostatistics) 

1988–1995. Since he retired in 2001, Dr. 

Bailar has been Scholar in Residence at 

the National Academies. Dr. Bailar 

received his M.D. from Yale University 

in 1955 and his Ph.D. in Statistics from 

American University in 1973. His areas 

of expertise include statistics, 

biostatistics, epidemiology, and 

environmental and occupational 

hazards. For many years his 

professional interests centered on the 

causes and prevention of disease. More 

recently he has focused on improving 

quality and performance in science 

generally, with a special focus on 

communication. Dr. Bailar has served 

on more than 40 committees at the 

National Academies, and served as chair 

or co-chair of 13 of these committees. 

Dr. Bailar has received numerous 

special/prestigious honors, awards and 

recognitions, including MacArthur 

Fellow 1990–1995, elected member to 

both the Institute of Medicine and the 

International Statistical Institute, 

honorary Fellow, American Medical 

Writers Association, and most recently 

an Honored Member of the Board of 

Editors in the Life Sciences. In addition, 

for 11 years, he was the statistical 

consultant and a member of the editorial 

board for The New England Journal of 

Medicine. Association memberships of 

Dr. Bailar include the American 

Statistical Association (life member) and 

Council of Science Editors (Past 

President). Dr. Bailar has more than 250 

scientific publications including articles 

in peer reviewed journals, books, book 

chapters, and proceedings, and has 

published widely in the statistics and 

epidemiology literature. 

2. James V. Bruckner, Ph.D., 

University of Georgia. 

i. Expertise: Toxicology (liver effects, 

neurotoxicology, and developmental/

reproductive) and Human Health Risk 

Assessment. 

ii. Education: University of Michigan, 

Ph.D. in Toxicology (1974). 

iii. Professional Experience: Dr. 

Bruckner is currently Professor of 

Pharmacology and Toxicology at the 

University of Georgia College of 

Pharmacy. He is also Professor in the 

Department of Physiology and 

Pharmacology at the University of 

Georgia College of Veterinary Medicine. 

He received his Ph.D. in Toxicology 

from the University of Michigan in 

1974. He has previously held faculty 

positions at the University of Kansas 

and the University of Texas Medical 

School at Houston. He is actively 

engaged in graduate education and in 

federally-funded research projects. Dr. 

Bruckner’s research focus is on the 

toxicology and toxicokinetics of 

solvents, drug-solvent interactions at 

occupational exposure levels, and 

toxicokinetic bases for susceptibility of 

children to insecticides and other 

chemicals. Dr. Bruckner has published 

more than 200 journal articles, book 

chapters, and abstracts. He has also 

served on a variety of expert panels and 

committees for the EPA, National 

Institutes of Health, National 

Aeronautics and Space Administration, 

Agency for Toxic Substances and 

Disease Registry, Food and Drug 

Administration, and National Academy 

of Sciences. 

3. Deborah A. Cory-Slechta, Ph.D., 

University of Rochester School of 

Medicine and Dentistry. 

i. Expertise: Toxicology 

(neurotoxicology and developmental/

reproductive) and Human Health Risk 

Assessment. 

ii. Education: University of 

Minnesota, Ph.D. in Experimental 

Psychology (1977). 

iii. Professional Experience: Dr. CorySlechta is currently a Professor in the 

Department of Environmental Medicine 

and the Department of Pediatrics at the 

University of Rochester School of 

Medicine and Dentistry, where she also 

serves as co-director of the Behavioral 

Sciences Facility Core and director of 

the Animal Behavior Core. Dr. CorySlechta received her Ph.D. from the 

University of Minnesota in 1977 and 

worked as a junior staff fellow of the 

Food and Drug Administration (FDA) 

National Center for Toxicological 

Research (NCTR) beginning in 1979. She 

was appointed to the faculty of the 

University of Rochester Medical School 

in 1982 and was appointed Chair of the 

Department of Environmental Medicine 

and Director of the National Institute of 

Environmental Health Sciences (NIEHS) 

Environmental Health Sciences Center 

at the University of Rochester in 1998. 

From 2000 to 2002, she was the Dean for 

Research and Director of the AAB 

Institute for Biomedical Sciences. 

Following her appointment as Dean, she 

served from 2003 to 2007 as the Chair 

of the Department of Environmental and 

Occupational Medicine at Robert Wood 

Johnson Medical School and as Director 

of the Environmental and Occupational 

Health Sciences Institute, a joint 

Institute of the Robert Wood Johnson 

Medical School and Rutgers. Dr. CorySlechta’s research has focused largely 

on environmental neurotoxicants as risk 

factors for behavioral disorders and 

neurodegenerative disease. These 

research efforts have resulted in over 

170 papers and book chapters to date. 

Dr. Cory-Slechta has served on 

numerous national research review and 

advisory panels, including committees 

of the National Institutes of Health, 

NIEHS, NCTR, EPA, National Academy 

of Sciences, Institute of Medicine, and 

the Agency for Toxic Substances and 

Disease Registry, Centers for Disease 

Control. In addition, Dr. Cory-Slechta 

has served on the editorial boards of 

several journals including 

Environmental Health Perspectives, 

Neurotoxicology, Toxicology, 

Toxicological Sciences, Fundamental 

and Applied Toxicology, 

Neurotoxicology and Teratology, and 

American Journal of Mental 

Retardation. She has held the elected 

positions of President of the 

Neurotoxicology Specialty Section of 

the Society of Toxicology, President of 

the Behavioral Toxicology Society, and 

been named a Fellow of the American 

Psychological Association. 

4. Jamie C. DeWitt, Ph.D., East 

Carolina University. 

i. Expertise: Toxicology 

(immunotoxicology, neurotoxicology, 

and developmental). 

ii. Education: Indiana University, 

Ph.D. in Environmental Science and 

Neural Science (2004). 

mstockstill on DSK4VPTVN1PROD with NOTICES

24422 Federal Register / Vol. 79, No. 83 / Wednesday, April 30, 2014 / Notices 

iii. Professional Experience: Dr. 

DeWitt is an Assistant Professor in the 

Department of Pharmacology and 

Toxicology at the Brody School of 

Medicine at East Carolina University 

(ECU). She is affiliated with The Harriet 

and John Wooten Laboratory for 

Alzheimer’s and Neurodegenerative 

Diseases Research and holds an adjunct 

appointment in the ECU Department of 

Public Health. Dr. DeWitt received her 

Ph.D. in Environmental Science and 

Neural Science from the School of 

Public and Environmental Affairs and 

Program in Neural Science at Indiana 

University in 2004. She also completed 

postdoctoral training in Developmental 

Cardiotoxicity at Indiana UniversityBloomington and in Immunotoxicology 

at EPA through a cooperative training 

agreement with the University of North 

Carolina at Chapel Hill. Dr. DeWitt’s 

main research focus is on how toxicants 

found in the environment can lead to 

neurodevelopmental and 

neurodegenerative disorders via 

disruption of the developing immune 

system. Much of her past research has 

involved the immunotoxicity of PFOA 

and related polyfluoroalkyl substances 

(PFASs). Dr. DeWitt has published 

seven peer reviewed research articles, 

three review papers and two book 

chapters that address the biological 

effects of PFOA, as well as one paper on 

the effects of PFOS on immune 

function. Her publications describe 

effects as well as underlying 

mechanisms following adult and 

developmental exposure. Her research 

experience and publication record 

(more than 25 peer reviewed 

manuscripts, 6 review articles, 9 book 

chapters) extend beyond the effects of 

perfluoroalkyl acids and working with 

rodent models. She is currently editing 

a book on the general toxicity of PFASs 

and is a current member of the 

mechanistic working group for 

Monograph 110 of the International 

Agency for Research on Cancer, which 

will include an assessment of PFOA. 

She is on the editorial boards of the 

Journal of Immunotoxicology and the 

Journal of Environmental Toxicology 

and Health and has reviewed grants for 

the U.S. Department of Defense and the 

National Institute of Occupational 

Safety and Health (NIOSH). She has also 

been a manuscript reviewer for more 

than 20 journals. Dr. DeWitt is the 

current president of the North Carolina 

chapter of the Society of Toxicology 

(SOT) and the Junior Councilor for the 

Immunotoxicology Specialty Section of 

the SOT. She also was awarded the 

Outstanding Young Investigator Award 

from the Immunotoxicology Specialty 

Section in 2013. 

5. Neeraja K. Erraguntla, Ph.D., DABT, 

Texas Commission on Environmental 

Quality. 

i. Expertise: Toxicology (liver effects, 

neurotoxicology, immunotoxicology, 

and developmental/reproductive) and 

Human Health Risk Assessment. 

ii. Education: Louisiana State 

University, Ph.D. in Physiology, 

Pharmacology, & Toxicology (1998). 

iii. Professional Experience: Dr. 

Erraguntla is currently a Senior 

Toxicologist/Project Manager at the 

Texas Commission on Environmental 

Quality (TCEQ). She is also an Adjunct 

Assistant Professor at Texas A&M 

School of Public Health. Dr. Erraguntla 

received her Ph.D. in Physiology, 

Pharmacology, and Toxicology from 

Louisiana State University in 1998. 

Prior to joining TCEQ, Dr. Erraguntla 

served as a Scientific Advisor at Life 

Technologies (2001–2004) and as a 

Research Fellow/Research Associate at 

the University of Texas Southwestern 

Medical Center (1998–2001). Dr. 

Erraguntla was board-certified as a 

Diplomate of the American Board of 

Toxicology in 2012. Her work focuses 

on air toxics, multimedia risk 

assessment, and development of toxicity 

factors for various industrial chemicals. 

This involves general review of 

toxicological studies, weight-ofevidence (WOE) analysis by the 

integration of science along multiple 

lines of evidence (epidemiology, in vivo 

& in vitro experimental toxicology, and 

human clinical studies) and advising 

staff on hazard classification. Dr. 

Erraguntla is also a team leader working 

on developing a framework for 

conducting systematic reviews and 

determining WOE for toxicity factors. 

Dr. Erraguntla has been an invited 

speaker at over eight national and state/ 

regional meetings. She is currently a 

member of EPA’s Science Advisory 

Board Environmental Justice Technical 

Guidance Panel and has been a member 

of EPA’s Acute Exposure Guideline 

Levels Committee. Dr. Erraguntla has 

also been a full member of the Society 

of Toxicology (SOT) since 2011 and has 

supported SOT’s Specialty Sections and 

Special Interest Groups. 

6. Penelope A. Fenner-Crisp, Ph.D., 

DABT, Independent Consultant. 

i. Expertise: Human Health Risk 

Assessment and Mode-of-Action. 

ii. Education: University of Texas 

Medical Branch, Ph.D. in Pharmacology 

(1968). 

iii. Professional Experience: Dr. 

Fenner-Crisp has over 35 years of 

experience in human health and 

ecological risk assessments and is 

currently an independent consultant 

after retiring from her position as the 

Executive Director of the International 

Life Sciences Institute (ILSI) Risk 

Science Institute (2000–2004). Prior to 

joining ILSI, Dr. Fenner-Crisp was 

employed by EPA, where she served in 

a variety of capacities for over 22 years 

(1978–2000) including Senior Science 

Advisor to the Director and Deputy 

Director of the Office of Pesticide 

Programs, Director of the Health Effects 

Division of the Office of Pesticide 

Programs, Director of the Health and 

Environmental Review Division of the 

Office of Pollution Prevention and Toxic 

Substances, and Senior Toxicologist in 

the Health Effects Branch of the Office 

of Drinking Water. She was a charter 

member of EPA’s Risk Assessment 

Forum (RAF), a group of EPA senior 

scientists who are experts in all areas of 

human, ecological, and exposure 

assessment, and served as the RAF chair 

from 1998 until her retirement from 

EPA in 2000. Dr. Fenner-Crisp received 

her Ph.D. in Pharmacology from the 

University of Texas Medical Branch in 

Galveston in 1968 and completed a 

Postdoctoral Fellowship in 

Pharmacology at Georgetown University 

Schools of Medicine and Dentistry 

(1971–1976), with an emphasis on 

reproductive endocrinology. Her 35 

years of experience includes hands-on 

practice, and management oversight, of 

all components of both human health 

and ecological risk assessments related 

to drinking water contaminants, 

industrial chemicals, pesticides and 

foodborne pathogens. Dr. Fenner-Crisp 

has served on numerous committees 

and panels including expert panels 

charged with the review of EPA 

Integrated Risk Information System 

documents, EPA Advisory Committees, 

EPA Science Advisory Board Drinking 

Water Committee, and several World 

Health Organization Panels, to name a 

few. She has also played a key role in 

the development of many EPA science 

policies, including the policy guidance 

for use of Monte Carlo analyses in 

exposure assessment, the cumulative 

risk conceptual framework, 

implementation of the cancer 

guidelines, and those relevant to 

implementation of the 1996 Food 

Quality Protection Act. Dr. Fenner-Crisp 

is a member of the Society of Toxicology 

since 1983, and the Society for Risk 

Analysis (SRA) since 1981, where she 

was the recipient of the SRA’s first Risk 

Practitioner award. She has been a 

Diplomate of the American Board of 

Toxicology since 1984 and served a 

four-year term on its Board of Directors 

from 2001–2005. Dr. Fenner-Crisp has 

mstockstill on DSK4VPTVN1PROD with NOTICES

Federal Register / Vol. 79, No. 83 / Wednesday, April 30, 2014 / Notices 24423 

been an invited speaker at over 100 

national and international meetings and 

workshops, and has authored or coauthored over 40 publications, 

including peer-reviewed journal 

articles, reports, and book chapters. 

7. Jeffrey W. Fisher, Ph.D., U.S. Food 

and Drug Administration. 

i. Expertise: Toxicology 

(developmental/reproductive), Human 

Health Risk Assessment, and 

Pharmacokinetic Models. 

ii. Education: Miami University of 

Ohio, Ph.D. in Zoology/Toxicology 

(1987). 

iii. Professional Experience: Dr. Fisher 

is currently a Research Toxicologist at 

the U.S. Food and Drug Administration 

(FDA), National Center for Toxicological 

Research. He was formerly a Professor 

in the Department of Environmental 

Health Science, College of Public Health 

at the University of Georgia (UGA). He 

joined UGA in 2000 and served as 

Department Head of the Department of 

Environmental Health Sciences from 

2000 to 2006 and Director of the 

Interdisciplinary Toxicology Program 

from 2006–2010. Prior to joining UGA, 

he spent most of his career at Wright 

Patterson Air Force Base, where he was 

Principal Investigator and Senior 

Scientist in the Toxics Hazards Division 

and Technical Advisor for the 

Operational Toxicology Branch. Dr. 

Fisher’s research interests are in the 

development and application of 

biologically based mathematical models 

to ascertain health risks from 

environmental, food-borne and 

occupational chemical exposures. Dr. 

Fisher’s modeling experience includes 

working with chlorinated and nonchlorinated solvents, fuels, pesticides, 

perchlorate and bisphenol A. He has 

developed physiologically-based 

pharmacokinetic (PBPK) models for use 

in cancer risk assessment, estimating 

lactational transfer of solvents, 

understanding in utero and neonatal 

dosimetry, quantifying metabolism of 

solvent mixtures and developing 

biologically motivated models for the 

hypothalamic-pituitary-thyroid axis in 

rodents and humans. Dr. Fisher has 

published over 140 papers on 

pharmacokinetics and PBPK modeling 

in laboratory animals and humans. He 

has served on several national panels 

and advisory boards for the U.S. 

Department of Defense, Agency for 

Toxic Substances and Disease Registry, 

EPA and non-profit organizations. He 

was a U.S. delegate for the North 

Atlantic Treaty Organization. Dr. Fisher 

served on the International Life 

Sciences Institute Steering Committee, 

which evaluated chloroform and 

dichloroacetic acid using EPA-proposed 

Carcinogen Risk Guidelines. He is Past 

President of the Biological Modeling 

Specialty Section of the Society of 

Toxicology, reviewer for several 

toxicology journals, and was CoPrincipal Investigator on a National 

Institutes of Health-supported workshop 

on Mathematical Modeling at the 

University of Georgia in the fall of 2003. 

Dr. Fisher was also a member of the 

National Academy of Sciences 

subcommittee on Acute Exposure 

Guideline Levels from 2004–2010 and 

for the EPA Science Advisory Board 

(SAB) (2007–2010). He is an ad hoc EPA 

SAB member for dioxin and perchlorate. 

Dr. Fisher is a Fellow of the Academy 

of Toxicological Sciences, an associate 

editor for Toxicological Sciences, and 

on the editorial board of Journal of 

Environmental Science and Health Part 

C Environmental Carcinogenesis & 

Ecotoxicology Reviews. 

8. William L. Hayton, Ph.D., The Ohio 

State University. 

i. Expertise: Membrane Transport, 

Pharmacokinetic Models, and Mode-ofAction. 

ii. Education: State University of New 

York, Ph.D. in Pharmaceutics (1971). 

iii. Professional Experience: Dr. 

Hayton is a Professor Emeritus in the 

College of Pharmacy at The Ohio State 

University. Dr. Hayton received a Ph.D. 

in Pharmaceutics from the State 

University of New York at Buffalo in 

1967. He was a member of the 

Washington State University College of 

Pharmacy faculty for 19 years, rising to 

Chair of the Pharmacology/Toxicology 

Graduate Program in 1982 and Acting 

Dean at the College of Pharmacy in 

1987. In 1990, he transferred to the Ohio 

State University as Chair of the Division 

of Pharmaceutics, where he later served 

as Associate Dean for the Graduate 

Programs and Research until his 

retirement in 2010. Dr. Hayton’s 

expertise is pharmacokinetics, 

particularly construction and validation 

of mathematical models that describe or 

explain the kinetics of complex 

biological systems. One recent research 

interest is characterization of the Fc 

receptor-mediated transport and 

catabolism of albumin and IgG in wild 

type and FcR knockout mice. A second 

recent project is the quantitative 

modeling of the female hypothalamuspituitary-gonad (HPG) axis in the female 

rainbow trout (Oncorhynchus mykiss). 

The model is based on and integrates 

the biology of gonadotropin, estrogen, 

androgen and maturational hormone 

signaling systems, and it includes key 

intermediate steps in the signaling 

pathways; viz., gonadotropin and sex 

steroid synthesis, hormone receptors 

and their corresponding mRNA levels. 

Dr. Hayton’s expertise extends to 

interspecies scaling of pharmacokinetic 

model parameter values and xenobiotic 

metabolism. Dr. Hayton is author or coauthor of over 100 peer-reviewed 

scientific publications and has held 

peer-reviewed grant support from the 

National Institutes of Health, EPA, U.S. 

Air Force Office of Scientific Research, 

U.S. Food and Drug Administration, and 

U.S. Fish and Wildlife Service. He 

previously served on the EPA Science 

Advisory Board Perfluorooctanoic Acid 

Risk Assessment Review Panel. 

9. Matthew P. Longnecker, Sc.D, M.D., 

National Institute of Environmental 

Health Sciences. 

i. Expertise: Epidemiology and 

Pharmacokinetic Models. 

ii. Education: Harvard School of 

Public Health, Sc.D. in Epidemiology 

(1989); Dartmouth Medical School, M.D. 

(1981). 

iii. Professional Experience: Dr. 

Longnecker, M.D., Sc.D., is the head of 

the Biomarker-based Epidemiology 

Group at the National Institute of 

Environmental Health Sciences 

(NIEHS). Dr. Longnecker received an 

M.D. from Dartmouth Medical School 

and completed a residency in internal 

medicine at Temple University Hospital 

in Philadelphia. After receiving a Sc.D. 

in Epidemiology from Harvard School of 

Public Health in 1989, he served as an 

Assistant Professor in the Department of 

Epidemiology at the University of 

California, Los Angeles, School Of 

Public Health. Since 1996, Dr. 

Longnecker has served as Adjunct 

Professor/Associate Professor in the 

Department of Epidemiology, School of 

Public Health, University of North 

Carolina at Chapel Hill. He came to the 

NIEHS Epidemiology Branch in 1995, as 

a tenure-track investigator. Dr. 

Longnecker’s research program is 

focused on the health effects of 

persistent organic pollutants (e.g., the 

DDT metabolite p,p’-DDE, and 

polychlorinated biphenyls). He is 

particularly interested in the effects of 

intrauterine exposure to persistent 

organic pollutants in relation to 

intrauterine growth, preterm birth, birth 

defects, neurologic findings at birth, 

growth, neurodevelopment, intelligence, 

and hearing. Recently, Dr. Longnecker 

has completed and has ongoing a series 

of studies on perfluorinated alkyl 

substances in relation to reproductive 

and pediatric outcomes. In addition, he 

has begun studying the effects of early, 

low-level exposure to the nonpersistent 

pollutants, bisphenol A and 

organophosphate pesticides. Dr. 

Longnecker’s research efforts have 

resulted in over 180 papers and book 

chapters to date. He has served as a 

mstockstill on DSK4VPTVN1PROD with NOTICES

24424 Federal Register / Vol. 79, No. 83 / Wednesday, April 30, 2014 / Notices 

leader for numerous national and 

international committees, such as for 

the Society for Epidemiologic Research 

and the International Society for 

Environmental Epidemiology, and has 

been on numerous national and 

international scientific advisory boards, 

including the EPA Science Advisory 

Board for the Perfluorooctanoic Acid 

Risk Assessment Review. 

10. Julie Melia, Ph.D., DABT, SRC, 

Inc. 

i. Expertise: Toxicology 

(neurotoxicology, developmental/

reproductive, liver effects), Human 

Health Risk Assessment, and Mode-ofAction. 

ii. Education: Northeastern 

University, Ph.D. in Biomedical 

Sciences/Toxicology (1990). 

iii. Professional Experience: Dr. Melia 

is currently a Senior Toxicologist at 

SRC, Inc. where she has served as 

Program Manager and provided 

toxicological support for several EPA 

programs and offices. She is also an 

Adjunct Scientist and member of the 

Maine Center for Toxicology and 

Environmental Health at the University 

of Southern Maine. She received her 

Ph.D. in Biomedical Sciences/

Toxicology from Northeastern 

University in 1990 and has 24 years of 

experience in the design and 

management of chemical toxicity 

evaluations and human health and 

ecological risk assessments. Prior to 

joining SRC in 2003, Dr. Melia was 

employed in the private sector, where 

she managed multidisciplinary project 

teams and contributed to more than 50 

Comprehensive Environmental 

Response, Compensation and Liability 

Act (CERCLA), Resource Conservation 

and Recovery Act (RCRA), and statedirected risk assessments. Dr. Melia was 

board-certified as a Diplomate of the 

American Board of Toxicology in 2004 

and has expertise in the critical review 

of mechanistic toxicology studies and 

the evaluation of chemical-specific 

modes of action. Dr. Melia has 

addressed complex toxicological issues 

related to human exposure to many 

chemicals including, phthalates, PAHs, 

polychlorinated biphenyls (PCBs), 

pesticides (DDT, kepone), chlorinated 

solvents, brominated trihalomethanes, 

1,4-dioxane, and ethanol. She has 

demonstrated innovative approaches to 

addressing challenging technical issues 

related to chemical toxicology and risk 

assessment and has significant 

experience in the critical review of 

epidemiology, toxicology, and 

mechanistic studies and the 

development of quantitative toxicity 

values. Dr. Melia has presented 

information to the EPA Science 

Advisory Board and has served as an 

external peer reviewer for Agency for 

Toxic Substances and Disease Registry 

Toxicological Profiles. She is a member 

of the Society of Toxicology, and the 

International Society of Regulatory 

Toxicology and Pharmacology. 

11. Andy L. Nong, Ph.D., Health 

Canada. 

i. Expertise: Pharmacokinetic Models. 

ii. Education: Universite ́ de Montre ́al, 

Ph.D. in Public Health (Toxicology) 

(2007). 

iii. Professional Experience: Dr. Nong 

is currently a Research Scientist at the 

Environmental Health Sciences and 

Research Bureau at Health Canada. He 

is also an Affiliate at the R. Samuel 

McLaughlin Centre for Population 

Health Risk Assessment within the 

University of Ottawa. He received his 

Ph.D. in Public Health from the 

Universite ́ de Montre ́al in 2007 and 

holds a Master’s degree in 

Pharmaceutical Sciences (2001). Prior to 

joining Health Canada, Dr. Nong served 

as Research Investigator (2008–2009) 

and Postdoctoral Fellow (2005–2008) at 

The Hamner Institutes for Health 

Sciences. His work has been recognized, 

in particular, for pharmacokinetics and 

biological modeling approaches in risk 

assessment. Specifically, his research 

program explores the use of biological 

computer models to simulate and 

interpret the fate and effects of chemical 

exposure. This work has led to deriving 

drinking water dose estimates, 

evaluating chemical mixture exposure, 

interpreting biomonitoring and 

exposure surveys, and investigating 

models for toxicity screening 

approaches for human equivalent 

chemical exposures. Dr. Nong is a 

member of the expert panel for Genome 

Canada’s Bioinformatics and 

Computational Biology roadmap. His 

international involvement includes a 

partnership with the EPA National 

Center for Computational Toxicology 

and Toxicity Forecaster (ToxCastTM) 

program, providing technical support 

for documents on PBPK modeling in 

risk assessment for EPA and the World 

Health Organization/International 

Program on Chemical Safety. Dr. Nong 

has authored and co-authored several 

publications, including peer-reviewed 

articles and book chapters, and served 

on the Board of Editors of the Journal of 

Applied Toxicology. 

12. Stephen M. Roberts, Ph.D., 

University of Florida. 

i. Expertise: Toxicology (liver effects 

and immunotoxicology) and Human 

Health Risk Assessment. 

ii. Education: University of Utah, 

Ph.D., Department of Pharmacology 

(1973). 

iii. Professional Experience: Dr. 

Roberts is a Professor at the University 

of Florida with joint appointments in 

the College of Veterinary Medicine, 

College of Medicine, and College of 

Public Health and Health Professions. 

He also serves as Director of the Center 

for Environmental & Human Toxicology 

at the University of Florida. Dr. Roberts 

received a Ph.D. from the University of 

Utah College of Medicine Department of 

Pharmacology in 1973. After a National 

Institutes of Health postdoctoral 

fellowship in pharmacokinetics at 

SUNY Buffalo (1977–1980), he served 

on the faculties of the University of 

Cincinnati College of Pharmacy (1980– 

1986) and the College of Medicine at the 

University of Arkansas for Medical 

Sciences (1986–1989). Dr. Roberts has 

been a faculty member at the University 

of Florida since 1989. His research 

addresses mechanisms of toxicity, 

particularly involving the liver and 

immune system. Dr. Roberts also has an 

active research program in 

toxicokinetics, especially involving 

bioavailability of environmental 

toxicants, as well as approaches to 

evaluation of potential toxicity of 

nanomaterials. His teaching 

responsibilities at the University of 

Florida include graduate courses in 

toxicology and risk assessment, as well 

as invited lectures in other graduate and 

professional courses. Dr. Roberts’ 

research efforts have resulted in over 

100 papers and book chapters to date, as 

well as over 100 published abstracts and 

letters. Dr. Roberts has served on 

numerous national advisory panels, 

including for the EPA, Department of 

Health and Human Services, and the 

Food and Drug Administration. He is 

currently the Associate Editor for 

Nanotoxicology and is currently or 

recently on the Editorial Boards of 

Toxicology and Applied Toxicology, 

Human and Ecological Risk Assessment, 

and Dose-Response. 

13. Angela L. Slitt, Ph.D., University 

of Rhode Island. 

i. Expertise: Toxicology (liver effects) 

and Membrane Transport. 

ii. Education: University of 

Connecticut, Ph.D. in Pharmacology and 

Toxicology (2000). 

iii. Professional Experience: Dr. Slitt 

is currently an Associate Professor in 

the Department of Biomedical and 

Pharmaceutical Sciences at the 

University of Rhode Island. Dr. Slitt 

received her Ph.D. in Pharmacology and 

Toxicology from the University of 

Connecticut in 2000, and then served 

until 2004 as a postdoctoral fellow at 

the University of Kansas Medical 

Center. Dr. Slitt has been a faculty 

member at the University of Rhode 

mstockstill on DSK4VPTVN1PROD with NOTICES

Federal Register / Vol. 79, No. 83 / Wednesday, April 30, 2014 / Notices 24425 

Island since 2006. Dr. Slitt’s graduate 

and postdoctoral training was heavily 

focused on liver biology and health, 

with a focus in the area of toxicology, 

and included research in nuclear 

receptors, biotransformation, and 

transporter expression. Her current 

research interests focus on how (1) 

expression of drug transporters affects 

chemical disposition and toxicity, (2) 

nutrition and intake of dietary 

antioxidants affects the expression of 

drug transporters, (3) liver disease (i.e., 

diabetes, cholestasis, and ethanol 

cirrhosis) affects transporter expression 

and chemical disposition, and (4) 

transporter expression affects 

cholesterol transport and susceptibility 

to gallstone formation. She has also 

recently investigated the effect of PFOS 

on caloric restriction in mice. Dr. Slitt 

is presently on the Editorial Board of 

BMC Pharmacology and Toxicology, 

Journal of Biochemical and Molecular 

Toxicology, and Toxicology Methods 

and Mechanism, and is an ad-hoc 

reviewer for numerous other journals. 

She is author or co-author of over 50 

peer-reviewed scientific publications, 

and was recently awarded the 

University of Rhode Island Early Career 

Faculty Research Excellence Award. 

14. Calvin C. Willhite, Ph.D., Risk 

Sciences International and McLaughlin 

Centre for Population Health Risk 

Assessment. 

i. Expertise: Toxicology 

(developmental/reproductive) and 

Human Health Risk Assessment. 

ii. Education: Dartmouth Medical 

School, Ph.D. in Pharmacology (1980). 

iii. Professional Experience: Dr. 

Willhite has more than 30 years of 

experience in the fields of toxicology 

and human health risk assessment. He 

is currently employed as a Contract 

Toxicologist for Risk Sciences 

International and McLaughlin Centre for 

Population Health Risk Assessment at 

the University of Ottawa, where he 

performs chemical-specific human 

health risk assessments for Health 

Canada and European Union REACH. 

Prior to his present employment, Dr. 

Willhite also conducted chemical 

specific risk assessment as a 

Toxicologist for the National Sanitation 

Foundation (2005–2012) and for the 

State of California (1985–2011). He 

received his Ph.D. in Pharmacology 

from the Dartmouth Medical School in 

1980. Dr. Willhite has more than 100 

publications in basic and applied 

toxicology and human health risk 

assessment. He has experience with 

many types of compounds including 

chemicals in occupational, submarine 

and ambient air; drugs in dermatology; 

endocrine-active drugs and 

environmental chemicals; inorganic 

elements; and dietary supplements. His 

editorial responsibilities include serving 

on the Editorial Board and/or as 

Reviewer of many peer reviewed 

toxicology journals. He is currently 

serving on the Editorial Board of 

Toxicology and Applied Toxicology, 

Journal of Toxicology, Journal of 

Toxicology and Environmental Health 

Part A, and the International Journal of 

Toxicology. He has been a member of 

the National Academy of Sciences 

Committee on Toxicology, EPA National 

Advisory Committee, American 

Conference of Industrial Hygienists, 

International Agency for Research on 

Cancer, Society of Toxicology, and 

National Institutes of Health advisory 

committees. 

15. Raymond G. York, Ph.D., DABT, 

Fellow-ATS, RG York and Associates, 

LLC. 

i. Expertise: Toxicology 

(developmental/reproductive and 

neurotoxicology). 

ii. Education: University of 

Cincinnati, Ph.D. in Toxicology (1982). 

iii. Professional Experience: Dr. York 

is a board-certified Toxicologist and 

operates his own consulting company, 

RG York and Associates, LCC. Dr. York 

received his Ph.D. in Toxicology at the 

University of Cincinnati Medical Center 

in 1982 and completed a two-year 

postdoctoral fellowship at the 

Children’s Hospital Research 

Foundation in Cincinnati in the area of 

developmental toxicology. He has 

previously served as Senior Scientific 

Director at WIL Research Laboratories 

(2008–2011), Associate Director of 

Research/Program Manager at Charles 

River Laboratories (1995–2008), and 

Director of Reproductive Toxicology 

and Neurotoxicology at International 

Research and Development Corporation 

(now MPI Research) (1989–1995). Dr. 

York was board-certified as a Diplomate 

of the American Board of Toxicology in 

1986 and served four years on its Board 

of Directors. His work focus is in the 

field of toxicology, particularly 

reproductive and developmental 

toxicology. Dr. York has served as a 

study director on over 700 safety 

evaluation studies, published over 100 

manuscripts, review articles, book 

chapters and abstracts, and has been an 

invited speaker at international 

conferences. He is currently on the EPA 

Science Advisory Board for 

trimethylbenzene. Dr. York has also 

been a member of the Society of 

Toxicology (SOT) since 1985 and the 

American College of Toxicology since 

1998. He is currently President of the 

Reproductive and Developmental 

Toxicology Specialty Section of SOT. In 

addition, Dr. York has been a member 

of the Teratology Society since 1984, 

and served as the President for both the 

Midwest Teratology Association (1989) 

and the Middle Atlantic Reproduction 

and Teratology Association (2004). He 

has served as a reviewer for Toxicology 

and Applied Pharmacology and 

International Journal of Toxicology and 

as a member of the Editorial Board of 

Fundamental and Applied Toxicology. 

Dated: April 22, 2014. 

Nancy K. Stoner, 

Acting Assistant Administer, Office of Water. 

[FR Doc. 2014–09888 Filed 4–29–14; 8:45 am] 

BILLING CODE 6560–50–P 

ENVIRONMENTAL PROTECTION 

AGENCY 

[FRL–9910–27–OA] 

Notification of a Request for 

Nominations of Experts for a Science 

Advisory Board Panel on EconomyWide Modeling 

AGENCY: Environmental Protection 

Agency (EPA). 

ACTION: Notice. 

SUMMARY: The EPA Science Advisory 

Board (SAB) Staff Office requests public 

nominations of scientific experts to form 

an SAB panel to provide advice through 

the chartered SAB on the appropriate 

role of economy-wide modeling of the 

costs and benefits of air regulations in 

informing the regulatory process. 

DATES: Nominations should be 

submitted by May 21, 2014 per the 

instructions below. 

FOR FURTHER INFORMATION CONTACT: Any 

member of the public wishing further 

information regarding this Notice and 

Request for Nominations may contact 

Dr. Holly Stallworth, Designated Federal 

Officer (DFO), SAB Staff Office, by 

telephone/voice mail at (202) 564–2073 

or via email at stallworth.holly@epa.gov. 

General information concerning the EPA 

SAB can be found at the EPA SAB Web 

site at http://www.epa.gov/sab. 

SUPPLEMENTARY INFORMATION: 

Background: The SAB (42 U.S.C. 

4365) is a chartered Federal Advisory 

Committee that provides independent 

scientific and technical peer review, 

advice, consultation, and 

recommendations to the EPA 

Administrator on the technical basis for 

EPA actions. As a Federal Advisory 

Committee, the SAB conducts business 

in accordance with the Federal 

Advisory Committee Act (FACA) (5 

U.S.C. App. 2) and related regulations. 

The SAB will comply with the 

mstockstill on DSK4VPTVN1PROD with NOTICES